Work

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Year: 2023

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.086

Authors: L. Emmett, S. Subramaniam, M. Crumbaker, A.M. Joshua, A.J. Weickhardt, S.T. Lee, S. Ng, R.J. Francis, J.C.H. Goh, D.A. Pattison, H. Tan, I.D. Kirkwood, S.K. Sandhu, A. Nguyen, C. Gedye, N. Rutherford, M. Hofman, A. Martin, M.R. Stockler, I.D. Davis

Institutions: St Vincent's Hospital Sydney, The University of Sydney, The Kinghorn Cancer Centre, Austin Health, Austin Hospital, Sir Charles Gairdner Hospital, The University of Western Australia, Royal Brisbane and Women's Hospital, Royal Adelaide Hospital, Peter MacCallum Cancer Centre, Calvary Mater Newcastle Hospital, Hunter New England Local Health District, Victorian Comprehensive Cancer Centre, Eastern Health, Monash University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387809611

Cites:

Cited by: 12

Related to: 10